BD Builds On Its Investment In China
In the early days of BD, its leaders determined that importing medical devices from Europe was less advantageous than manufacturing in the United States for the domestic medical profession. What followed was investment in infrastructure, acquisition of tools and the hire of qualified staff. This successful business model is being applied in China today by BD.
Since establishing representative offices in China in 1994, the country has been the focus of increased investment by BD, with three manufacturing facilities in Suzhou, Jiangsu Province, making products ranging from catheters and insulin pen needles to rapid diagnostic products for influenza and viral infections. Nearly 3,000 employees contribute to management, production and sales.
Today, BD takes the next step by opening a new Research and Development (R&D) Center in Suzhou. Its core mission will include strategic innovation and new product development, optimization of the product portfolio and support for local registration of new products. The R&D Center will be where research, experiments, and application of research results in production will be carried out.
The Suzhou R&D Center joins a similar BD facility in Shanghai, focused on identifying the needs of local healthcare professionals and patients. In addition, BD is breaking ground at Suzhou for the purpose of manufacturing prefillable syringe components to support the rapid growth of China’s pharmaceutical market and to meet the needs of Chinese patients and pharmaceutical companies for prefillable syringe components.
A ribbon-cutting ceremony and tour of the new R&D facility was attended by BD leaders from the U.S., Greater Asia and Greater China, along with Chinese government officials as well as many BD customers. James Deng, Senior Vice President and General Manager of BD Greater China remarked, “Since 1994, BD has been building up a high-quality, localized multinational company, and has grown together with the Chinese healthcare industry. BD demonstrates confidence in the China market, through our continuing investment in the R&D center and production line.”
Jason Hwang, R&D Director, Greater China said, “Innovation has driven BD's growth for over a century through an integration of technology and a focus on underserved healthcare needs. The China R&D Center aims to sustain our strong growth in China with new solutions and services that cater to the unmet needs of local customers and patients in this large and dynamic market.”
Louis Yuan, Business Director of Pharmaceutical Systems, BD China, remarked, “Local production enables more flexible product supply and timely customer service. We expect to create values for the development of China pharmaceutical enterprises as well as the entire industry.”
The founding partners of BD would surely approve.